Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-08-15
1998-12-22
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4271931, 4272771, 530300, 530328, 422 61, 206570, A61K 3900, A61K 39385
Patent
active
058515232
ABSTRACT:
Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
W. F. Paul (ed.), Fundamental Immunology, 3rd edition, pp. 116-117, 517-518, 739-740, 775, and 1402. Raven Press, New York, 1993.
Townsend et al., The Epitopes of Influenza Nucleoprotein Recognized-by Cytotoxic T Lymphocytes Can Be Defined With Short Synthetic Peptides, Cell 44: 959-968 (Mar. 28, 1986).
Bjorkman et al., "The foreign antigen binding site and T cell-recognition regions of class I histocompatibility antigens", Nature 329: 512-518 (Oct. 8, 1987).
Van der Bruggen et al., "A Gene Encoding an Antigenic Recognized-by Cytolytic T Lymphocytes on a Human Melanoma", Science 254: 1643-1647 (1991).
Traversari et al., "A Nonapeptide Encoded by Human Gene MAGE-1-Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E", J. Exp. Med 176: 1453-1457 (Nov. 1992).
Celis et al., "Induction of anti-tumor cytotoxic T lymphocytes-in normal humans using primary cultures and synthetic peptide epitopes", Proc. Natl. Acad. Sci. USA 91: 2105-2109 (Mar. 1994).
Coulie et al., "A New Gene Coding for a Differentiation Antigen-Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas", J. Exp. Med. 180: 35-42 (Jul., 1994) (Not Prior Art).
Engelhard et al., "Structure of Peptides Associated with Class-I and Class II MHC Molecules", Ann. Rev. Immunol. 12: 181-207 (1994).
Ruppert et al., "Prominent Role of Secondary Anchnor Residues in-Peptide Binding to HLA-A2.1 Molecules", Cell 74: 929-937 (Sep. 10, 1993).
Bastin Judy
Boon-Falleur Thierry
Coulie Pierre
Gajewski Thomas
Townsend Alan
Cunningham Thomas M.
Ludwig Institute for Cancer Research.
LandOfFree
Isolated, peptides derived from MAGE tumor rejection antigen pre does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated, peptides derived from MAGE tumor rejection antigen pre, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated, peptides derived from MAGE tumor rejection antigen pre will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2043286